Dosage guide · 10 mg vial

Ipamorelin Dosage Protocol

Selective growth hormone secretagogue · ghrelin-receptor peptide

The reference protocol uses 100 mcg once daily in weeks 1-2, increasing to 250 mcg once daily by weeks 9-12. The default 10 mg + 3 mL mix is 3.33 mg/mL, so the 100 mcg starting amount is 3 units on a U-100 syringe. Human studies have not validated this subcutaneous schedule.

How oftenOnce daily

Starting dose100 mcg

Start = units3 units

Mix3 mL BAC water

Reviewed 25 Oct 2026 · Education only, not medical advice

Ipamorelin 10 mg vial

View on Peak Peptides Also at Pure Performance

Exact Peak Peptides Australia product photo

Dosage chart How to mix Supplies Calculator About Ipamorelin References

01 · DOSAGE CHART

Ipamorelin dosage chart

Gradual daily approach · 10 mg vial + 3 mL BAC water

BAC water added

Concentration3.33 mg/mL

1 unit (U-100)33.3 mcg= 0.01 mL

How oftenOnce dailySubcutaneous injection

3 mL is the PeptideDosages reference mix cited on Peak's Ipamorelin page, making 100 mcg equal 3 units.

Ipamorelin dosage chart for a 10 mg vial mixed with 3 mL of bacteriostatic water
Week	Daily dose	Syringe units
Weeks 1–2Start	100 mcg	3 units0.03 mL
Weeks 3–4	150 mcg	4.5 units0.045 mL
Weeks 5–8	200 mcg	6 units0.06 mL
Weeks 9–12Maintenance	250 mcg	7.5 units0.075 mL

Once daily · any consistent time · subcutaneous injection

The attributed reference protocol increases the daily amount every 2 to 4 weeks.

This is a 12-week educational schedule; it is not a clinically established subcutaneous regimen.

Community-reported amounts - Ipamorelin has no approved or clinically established subcutaneous dose. Education only, not medical advice. Dose amounts adapted from Ipamorelin 10 mg vial dosage protocol (PeptideDosages.com); units are recalculated for the vial and mix selected above.

02 · HOW TO MIX

Mixing a 10 mg vial with 3 mL of BAC water

Using a 1 mL (100-unit) insulin syringe, 3 full draws of bacteriostatic water gives 3.33 mg/mL.

1
Add the water slowly
Wipe both rubber stoppers with an alcohol swab and let them dry. Draw 3 mL of bacteriostatic water and let it run slowly down the inside of the vial wall — not straight onto the powder.
2
Swirl gently
Swirl or roll the vial gently until the powder has dissolved. Give it a few minutes to settle if needed.
3
Don't shake it
Shaking can damage the peptide and cause foaming. Gentle swirling only.
4
Check it's fully clear
Only use it once it is fully clear with no particles. Label the vial with the date and 3.33 mg/mL, then store it in the fridge at 2–8 °C.

Full illustrated reconstitution guide

03 · SUPPLIES NEEDED

What you'll need

Counts follow the dosage chart above at the highest amount in each step, using a 10 mg vial mixed with 3 mL.

Length of protocol

1Ipamorelin 10 mg vial9.1 mg needed in total

571 mL insulin syringesU-100, 27–31G · one per draw + one per vial mixed

1BAC water 10 mL bottle3 mL used for mixing

114Alcohol swabsSkin + stopper, every time

Plus an approved sharps container. Syringes and swabs are sold by Australian pharmacies — Peak Peptides and Pure Performance supply the bacteriostatic water.

Ipamorelin 10 mg vialPeak Peptides Australia Ipamorelin 10 mg vialPure Performance Australia

Peak Peptides Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPeak Peptides Australia

Pure Performance Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPure Performance Australia

04 · CALCULATOR

Check a different amount

Enter your vial, water and dose to see the matching syringe units.

Concentration Calculator

Labelled Vial Amount (mg)

Verified Final Liquid Volume3 mL

Amount to Evaluate (not a recommendation)

mcg

Concentration

3.33 mg/mL

(3333 mcg/mL)

Calculated Liquid Volume

0.030 mL

Equivalent U-100 volume scale position

3markings (not biological IU)

Illustration of a U-100 volume scale, not preparation or injection guidance

05 · PROTOCOL DETAILS

About Ipamorelin

Protocol overview

Starting dose: 100 mcg once daily for weeks 1-2
How it increases: 150 mcg in weeks 3-4, 200 mcg in weeks 5-8, then 250 mcg
Frequency: Once daily
When to take it: The attributed reference suggests 30-60 minutes before bedtime on an empty stomach
Cycle length: 12 weeks in the attributed reference schedule
Common mix: 3 mL bacteriostatic water -> 3.33 mg/mL

Storage

Before mixing: Store dry, protected from light, at 2-8 C short term or -20 C long term.
After mixing: Refrigerate at 2-8 C, upright and protected from light; follow the product's stated use-by period.
Never: Avoid repeated freeze-thaw and do not use a solution that remains cloudy or contains particles.

How it works

Ipamorelin is a synthetic pentapeptide studied as a growth hormone secretagogue at the ghrelin receptor, also called the growth hormone secretagogue receptor. It prompts a growth-hormone release signal rather than supplying growth hormone itself.

In rat-cell and animal experiments, ipamorelin stimulated growth-hormone release through a GHRP-like receptor pathway. In swine, its ACTH and cortisol response was not significantly different from the growth-hormone-releasing-hormone comparison, unlike the GHRP-2 and GHRP-6 comparators.

In a human intravenous-infusion study, the measured growth-hormone response was a single short episode. This does not establish long-term outcomes or validate the subcutaneous schedule above.

Illustrated mechanism explainer

What the research shows

A human PK/PD study gave five 15-minute intravenous infusion rates, 4.21 to 140.45 nmol/kg, to eight healthy men at each level. It estimated a 2-hour terminal half-life and a growth-hormone peak at 0.67 hours.
A postoperative-ileus trial enrolled 117 people, with 114 in the safety and modified intention-to-treat populations. Intravenous ipamorelin 0.03 mg/kg twice daily for up to 7 days did not show a significant difference from placebo in the primary or secondary efficacy analyses.
The postoperative trial reported median time to a tolerated solid meal of 25.3 hours with ipamorelin and 32.6 hours with placebo, p=0.15.
The human studies opened used intravenous administration. They do not establish the reference site's daily subcutaneous amounts, bedtime timing or 10 mg vial schedule.
The current Australian Poisons Standard lists IPAMORELIN in Schedule 4. Peak's product listing states that its 10 mg research vial is not approved by the TGA.

Reported side effects

Long-term safety data for repeated subcutaneous use are not established. FDA says it has not identified safety-related information for certain other injectable routes and lacks sufficient information to know whether ipamorelin acetate would cause harm by those routes.
FDA says compounded ipamorelin acetate may pose immunogenicity risk from aggregation or peptide-related impurities, and its unnatural amino acids add complexity to peptide characterisation.
In the short postoperative surgical trial, any treatment-emergent adverse event occurred in 87.5% of the ipamorelin group and 94.8% of the placebo group. This monitored intravenous setting does not estimate adverse-event rates for community subcutaneous use.
The TGA warns that unapproved injected peptide products can carry contamination, infection and local-tissue-damage risks, alongside uncertainty about sterility, ingredients and side effects.

Important notes

The current Australian Poisons Standard lists Ipamorelin in Schedule 4, and Peak states its 10 mg listing is not TGA approved. The TGA says unapproved peptides have not been evaluated for safety, quality or effectiveness.
Prohibited in sport at all times: WADA lists ipamorelin under S2.2.4, growth hormone secretagogues and their mimetics.
The chart is attributed to a community reference site. Published human studies used intravenous infusions, not this daily subcutaneous schedule.
Peak's listing says it has no product-specific LabDoc report; a purity figure or report for a different product does not verify this vial's identity, content or sterility.
Never use a mixed vial that is cloudy or has particles in it.

Injection basics

Use a new sterile 1 mL (100-unit) U-100 insulin syringe, 27–31G, every time — never reuse or share.
Wipe the vial stopper and the skin with an alcohol swab and let both dry first.
Inject under the skin (subcutaneously) of the abdomen, thigh or upper arm, and rotate sites.
Put used syringes straight into an approved sharps container — the NDSS lists Australian disposal options.

Guidance: World Health Organization · National Diabetes Services Scheme (NDSS)

06 · QUICK ANSWERS

Ipamorelin questions

How many units is 100 mcg of Ipamorelin?

With 3 mL in a 10 mg vial, the concentration is 3.33 mg/mL. A 100 mcg amount is 3 units, or 0.03 mL, on a U-100 syringe.

How many units is 250 mcg of Ipamorelin?

With the default 10 mg + 3 mL mix at 3.33 mg/mL, 250 mcg is 7.5 units, or 0.075 mL, on a U-100 syringe.

How much bacteriostatic water for Ipamorelin 10 mg?

The default is 3 mL, which makes 3.33 mg/mL. At this concentration, 1 mg is 30 units, or 0.3 mL, on a U-100 syringe. Peak cites this PeptideDosages reference mix; Pure's listing instead describes a 2 mL mix.

How long does a 10 mg Ipamorelin vial last?

At one daily amount, a 10 mg vial contains 100 amounts of 100 mcg, about 66.7 amounts of 150 mcg, 50 amounts of 200 mcg or 40 amounts of 250 mcg. The full 12-week chart totals 16.1 mg, so it requires 2 vials.

07 · SOURCES